DROPLET-BC study is a prospective clinical trial based in the U.S. to evaluate the performance of our PREMIR blood test for early detection of breast cancer
The goal of DROPLET-BC is to classify breast cancer patients from non-cancer volunteers by assessing the profile of circulating small-noncoding RNA in the blood with statistical validation. 1,200 individuals are expected to be enrolled. Information from this study will be utilized to develop a new method of breast cancer screening.
Further information at Clinicaltrials.gov